Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

HORIZON-Plus: An Open-Label Extension of the HORIZON Protocol (DIM20) Evaluating the Safety of Dimebon (Latrepirdine) in Subjects With Huntington Disease

NCT01085266 is registered in ClinicalTrials.gov with Medivation, Inc. as lead sponsor.

NCT NCT01085266
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01085266 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
HORIZON-Plus: An Open-Label Extension of the HORIZON Protocol (DIM20) Evaluating the Safety of Dimebon (Latrepirdine) in Subjects With Huntington Disease
Lead sponsor
Medivation, Inc.
Phase
Phase 3
Overall status
Terminated
Start date
February 28, 2010
Completion date
Not reported
Enrollment
362 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

huntington disease